AXGN vs. EDAP, ZYXI, SMLR, ELMD, OM, FONR, VANI, CUTR, BLFS, and CERS
Should you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Edap Tms (EDAP), Zynex (ZYXI), Semler Scientific (SMLR), Electromed (ELMD), Outset Medical (OM), FONAR (FONR), Vivani Medical (VANI), Cutera (CUTR), BioLife Solutions (BLFS), and Cerus (CERS).
Edap Tms (NASDAQ:EDAP) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, community ranking, media sentiment, risk, profitability, earnings and institutional ownership.
AxoGen received 101 more outperform votes than Edap Tms when rated by MarketBeat users. Likewise, 72.59% of users gave AxoGen an outperform vote while only 62.89% of users gave Edap Tms an outperform vote.
62.7% of Edap Tms shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 0.2% of Edap Tms shares are held by company insiders. Comparatively, 7.2% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Edap Tms has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.
AxoGen has a net margin of -13.66% compared to AxoGen's net margin of -35.03%. Edap Tms' return on equity of -22.38% beat AxoGen's return on equity.
In the previous week, Edap Tms had 2 more articles in the media than AxoGen. MarketBeat recorded 3 mentions for Edap Tms and 1 mentions for AxoGen. Edap Tms' average media sentiment score of 0.00 beat AxoGen's score of -0.05 indicating that AxoGen is being referred to more favorably in the news media.
Edap Tms currently has a consensus target price of $14.67, suggesting a potential upside of 101.47%. AxoGen has a consensus target price of $10.67, suggesting a potential upside of 60.88%. Given AxoGen's higher possible upside, research analysts clearly believe Edap Tms is more favorable than AxoGen.
AxoGen has higher revenue and earnings than Edap Tms. AxoGen is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.
Summary
AxoGen beats Edap Tms on 13 of the 17 factors compared between the two stocks.
Get AxoGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
